

# Cervical Dystonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/C6C2225AA432EN.html>

Date: May 2024

Pages: 138

Price: US\$ 6,499.00 (Single User License)

ID: C6C2225AA432EN

## Abstracts

The 7 major cervical dystonia markets reached a value of US\$ 148.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 270.0 Million by 2034, exhibiting a growth rate (CAGR) of 5.61% during 2024-2034.

The cervical dystonia market has been comprehensively analyzed in IMARC's new report titled "Cervical Dystonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cervical dystonia, which is also known as spasmodic torticollis, refers to a neurological disorder that causes involuntary muscle contractions in the neck, leading to aberrant movements and postures of the neck and head. Depending on the causative factor, cervical dystonia is classified as primary (idiopathic) and secondary (symptomatic). The symptoms of this disease can range from mild to severe. Some common indications include head twisting in various directions, jerking motion of the head, chin towards the shoulder, neck pain extending to the shoulders, etc. Additionally, individuals suffering from the ailment may experience disabling pain, fatigue, a raised shoulder, hand tremors, enlargement of the neck muscle, headaches, etc. The diagnosis of the condition is based on a review of the patient's clinical features, medical history, and physical exam. The healthcare provider may also perform several diagnostic tests and procedures, such as blood workups, magnetic resonance imaging (MRI), electromyography (EMG), etc., to confirm a diagnosis and dismiss other possible causes of underlying symptoms.

The rising prevalence of neurological disorders, which cause abnormalities in the basal ganglia or other brain areas that control body movement, is primarily driving the cervical dystonia market. In addition to this, the increasing incidence of various risk factors, including advancing age, head or neck trauma, family history of dystonia, genetic

mutations, etc., is also bolstering the market growth. Moreover, the widespread adoption of effective medications, such as anticholinergics, GABAergics, anticonvulsants, dopaminergics, etc., to treat disease symptoms is acting as another significant growth-inducing factor. Apart from this, the inflating application of biofeedback therapy, which helps improve mind-body connection and relax muscles to regulate involuntary body processes, is also propelling the market growth. Additionally, multiple key players are making extensive investments in R&D activities to launch new assessment tools with excellent sensitivity and specificity for early disease diagnosis. This, in turn, is creating a positive outlook for the market. Furthermore, the emerging popularity of deep brain stimulation for treating the ailment on account of its several associated benefits, such as reduced muscle contractions and long-lasting relief from symptoms, is expected to drive the cervical dystonia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the cervical dystonia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cervical dystonia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cervical dystonia market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom

Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the cervical dystonia market  
Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the cervical dystonia market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current cervical dystonia marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the cervical dystonia market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the cervical dystonia market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the cervical dystonia market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of cervical dystonia across the seven major markets?

What is the number of prevalent cases (2018-2034) of cervical dystonia by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of cervical dystonia by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with cervical dystonia across the seven major markets?

What is the size of the cervical dystonia patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of cervical dystonia?

What will be the growth rate of patients across the seven major markets?

### Cervical Dystonia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for cervical dystonia drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the cervical dystonia market?

What are the key regulatory events related to the cervical dystonia market?

What is the structure of clinical trial landscape by status related to the cervical dystonia market?

What is the structure of clinical trial landscape by phase related to the cervical dystonia market?

What is the structure of clinical trial landscape by route of administration related to the cervical dystonia market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 CERVICAL DYSTONIA - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 CERVICAL DYSTONIA - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 CERVICAL DYSTONIA - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 CERVICAL DYSTONIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 CERVICAL DYSTONIA - UNMET NEEDS**

## **10 CERVICAL DYSTONIA - KEY ENDPOINTS OF TREATMENT**

## **11 CERVICAL DYSTONIA - MARKETED PRODUCTS**

- 11.1 List of Cervical Dystonia Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Myobloc (Botulinum toxin B) - Supernus Pharmaceuticals
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets
  - 11.1.2 Xeomin (Botulinum toxin A) - Merz Pharma
    - 11.1.2.1 Drug Overview



- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Botox (Onabotulinum toxin A) - AbbVie
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Dysport (Botulinum toxin A) - Ipsen
  - 11.1.4.1 Drug Overview
  - 11.1.4.2 Mechanism of Action
  - 11.1.4.3 Regulatory Status
  - 11.1.4.4 Clinical Trial Results
  - 11.1.4.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 CERVICAL DYSTONIA - PIPELINE DRUGS**

- 12.1 List of Cervical Dystonia Pipeline Drugs Across the Top 7 Markets
  - 12.1.1 DaxibotulinumtoxinA - Revance Therapeutics
    - 12.1.1.1 Drug Overview
    - 12.1.1.2 Mechanism of Action
    - 12.1.1.3 Clinical Trial Results
    - 12.1.1.4 Safety and Efficacy
    - 12.1.1.5 Regulatory Status
  - 12.1.2 ABP - 450 - Daewoong Pharmaceuticals
    - 12.1.2.1 Drug Overview
    - 12.1.2.2 Mechanism of Action
    - 12.1.2.3 Clinical Trial Results
    - 12.1.2.4 Safety and Efficacy
    - 12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. CERVICAL DYSTONIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. CERVICAL DYSTONIA – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 CERVICAL DYSTONIA - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Cervical Dystonia - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Cervical Dystonia - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Cervical Dystonia - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Cervical Dystonia - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034)
  - 15.3.3 Cervical Dystonia - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Cervical Dystonia - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Cervical Dystonia - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Cervical Dystonia - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Cervical Dystonia - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Cervical Dystonia - Market Size by Therapies

- 15.5.2.1 Market Size by Therapies (2018-2023)
- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Cervical Dystonia - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Cervical Dystonia - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Cervical Dystonia - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Cervical Dystonia - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Cervical Dystonia - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Cervical Dystonia - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Cervical Dystonia - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Cervical Dystonia - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Cervical Dystonia - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Cervical Dystonia - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Cervical Dystonia - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Cervical Dystonia - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Cervical Dystonia - Access and Reimbursement Overview

## **16 CERVICAL DYSTONIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 CERVICAL DYSTONIA MARKET - SWOT ANALYSIS**

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

## **18 CERVICAL DYSTONIA MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Cervical Dystonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/C6C2225AA432EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C6C2225AA432EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

